Replay available

Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call

Harvard Bioscience, Inc. (NASDAQ: HBIO) Q2 2026 earnings conference call, held 2026-08-11. Replay captured from the company's public earnings webcast.

Tue, August 11, 2026 at 8:00 AMendedReplay
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Taylor Krafchick

Senior Vice President at Ellipsis

John Duke

President and Chief Executive Officer

Mark Frost

Chief Financial Officer

Paul Knight

Analyst, KeyBank Capital Markets

Bruce Jackson

Analyst, StoneX

Replay transcript excerpt

Good day and welcome to the second quarter, 2026 Harvard Bioscience Earnings Conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star 1-1 on your touchstone telephone. Please note this call is being recorded. I would like to turn the call over to Taylor Krafchick, Senior Vice President at Ellipsis. Please go ahead. Thank you, operator, and good morning, everyone. Thank you for joining the Harvard Bioscience Second Quarter 2026 Earnings Conference Call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer. In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks that is posted to our investor relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management's expectations of future events or future financial performance, are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience Management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Forum 10Q, and others, filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties, and contingencies associated therewith. During th...

More from Harvard Bioscience, Inc.